Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;38(6):1020-1030.
doi: 10.1111/fcp.13031. Epub 2024 Aug 5.

Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management

Shubhangi Saxena  1 , Neha Dagar  1 , Vishwadeep Shelke  1 , Bhupendra Puri  1 , Anil Bhanudas Gaikwad  1
Affiliations
Review

Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management

Shubhangi Saxena et al. Fundam Clin Pharmacol. 2024 Dec.

Abstract

Background: Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on β-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β-catenin signalling for CKD management is of utmost relevance.

Objectives: The primary aim of this review is to highlight the significance of targeting Wnt/β-catenin signalling for CKD management.

Methods: The literature review regarding the role of Wnt/β-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.

Results: The current review summarises the pharmacological therapies modulating the Wnt/β-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.

Conclusion: Wnt/β-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β-catenin signalling have emerged as effective means for alleviating CKD.

Keywords: Wnt/β‐catenin signalling; canonical Wnt/β‐catenin pathway; chronic kidney disease; non‐canonical Wnt/β‐catenin pathway; targeted therapies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Nephrol. Dial. Transplant. 2019;34(11):1803‐1805. doi:10.1016/j.kint.2019.07.012
    1. van der Wal T, van Amerongen R. Walking the tight wire between cell adhesion and WNT signalling: a balancing act for β‐catenin. Open Biol. 2020;10(12):200267. doi:10.1098/rsob.200267
    1. Zhang W, Wang S, Yin H, et al. Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β‐catenin signaling pathway. Fundam. Clin. Pharmacol. 2016;30(6):596‐606. doi:10.1111/fcp.12225
    1. Sanchez‐Ferras O, Pacis A, Sotiropoulou M, et al. A coordinated progression of progenitor cell states initiates urinary tract development. Nat. Commun. 2021;12(1):2627. doi:10.1038/s41467‐021‐22931‐5
    1. He X, Cheng R, Huang C, et al. A novel role of LRP5 in tubulointerstitial fibrosis through activating TGF‐β/Smad signaling. Signal Transduct. Target. Ther. 2020/04/29. 2020;5(1):45. doi:10.1038/s41392‐020‐0142‐x

MeSH terms

LinkOut - more resources